[Effect of orlistat on postprandial glycemia in the oral glucose tolerance test and on other metabolic parameters in patients with type 2 diabetes].
The impact of monotherapy with an enteric lipase inhibitor (orlistat) on postprandialglycemia in the oral glucose tolerance test (OGTT) and on other metabolic parameters was studied in obese patients with type 2 diabetes (T2D). The study included 26 patients aged S3.07±6.70 years, who had a 2.60±2.91-year history of mild T2D. All the patients were given orlistat, 120 mg, as a capsule thrice daily before meals. Orlistat treatment was performed along with a low-calorie (as high as 1200 kcal daily) diet whose keeping was monitored by an individual dietary diary. During orlistat therapy, significant reductions were found in body weight (BW), body mass index, and waist circumference. At the same time, just within the first month and most patients were observed to lose up to 5% of the В W, but by the end of treatment there was a weight reduction by more than 5% of the baseline. Orlistat therapy caused a significant decrease in the fasting and postprandial blood levels of glucose and, accordingly, glycated hemoglobin. Orlistat induced a significant reduction in the total level of total cholesterol and low-density lipoproteins. By the end of the study, there was a significant decrease in systolic and diastolic blood pressures.